Tyroserleutide

• UNSPSC Description:

  Tyroserleutide (YSL), isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].

• Target Antigen:

  Others

• Type:

  Peptides

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tyroserleutide.html

• Solubility:

  H2O

• Smiles:

  CC(C)C[C@@H](C(O)=O)NC([C@H](CO)NC([C@@H](N)CC1=CC=C(O)C=C1)=O)=O

• Molecular Weight:

  381.42

• References & Citations:

  [1]Wang C, et al. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol. 2003 Aug;33(3):189-95.|[2]Liang P, et al. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy. Adv Healthc Mater. 2019 Aug;8(15):e1900306.|[3]Yao Z, Qiu S, Wang L, et al. Tripeptide tyroserleutide enhances the antitumor effects of macrophages and stimulates macrophage secretion of IL-1beta, TNF-alpha, and NO in vitro. Cancer Immunol Immunother. 2006;55(1):56-60. |[4]Ma C, Wei T, Hua Y, Wang Z, Zhang L. Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma. Int J Nanomedicine. 2021;16:4495-4513.|[5]Che X, Lu R, Fu Z, et al. Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9. Drug Des Devel Ther. 2018;12:3357-3368.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  138168-48-6